Association between recurrent breast cancer and phthalate exposure modified by hormone receptors and body mass index

The association between phthalate exposure and breast cancer remains controversial. We performed a prospective patient cohort design to explore the interaction between creatinine-corrected urinary phthalate metabolites and hormone receptors as well as body mass index (BMI) on recurrent breast cancer...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2022-02, Vol.12 (1), p.2858-2858, Article 2858
Main Authors: Yang, Pei-Jing, Hou, Ming-Feng, Ou-Yang, Fu, Hsieh, Tsung-Hua, Lee, Yen-Jung, Tsai, Eing-Mei, Wang, Tsu-Nai
Format: Article
Language:English
Subjects:
631/67/1347
692/4028/67/1347
692/499
692/53/2423
692/699/67/1347
692/699/67/2324
Adult
Aged
Body Mass Index
Breast cancer
Breast Neoplasms - etiology
Creatinine
Environmental Exposure - adverse effects
ErbB-2 protein
Female
Humanities and Social Sciences
Humans
Metabolites
Middle Aged
multidisciplinary
Negative Results
Neoplasm Recurrence, Local - etiology
Phthalates
Phthalic Acids - adverse effects
Prospective Studies
Science
Science (multidisciplinary)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The association between phthalate exposure and breast cancer remains controversial. We performed a prospective patient cohort design to explore the interaction between creatinine-corrected urinary phthalate metabolites and hormone receptors as well as body mass index (BMI) on recurrent breast cancer. In this follow-up study, 636 female breast cancer patients and 45 new recurrent cases diagnosed for a total of 1576.68 person-years of follow-up were recruited. Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP) was negatively associated with breast cancer recurrence, with adjusted hazard ratio (aHR) 3rd vs. 1st quartile of 0.15 (95% CI 0.04–0.51). The MEOHP presented as a non-monotonic dose–response (NMDR) curve, being U-shaped. In the stratification of hormone receptors, MEOHP still exhibited a U-shaped dose–response curve. The third quartile of MEOHP showed significant lowest recurrent risk in the status of ER-positive (aHR 0.18, 95% CI 0.05–0.66), PR-negative (aHR 0.14, 95% CI 0.03–0.63), and HER2-negative (aHR 0.24, 95% CI 0.08–0.76). Whether in BMI 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-06709-3